Rovelizumab
Based on 1 publication(s) in Google Scholar
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.23%
- CAS No.: 339086-79-2
- Masse moléculaire:145.98 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Rovelizumab
More
Activité biologique
Human IgG4 kappa
Human
ITGAL & ITGB2
Rovelizumab binds CD18 and has activity against CD18-integrin complexes including the CD11b-CD18 heterodimer[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 339086-79-2
-
Appearance Liquid
-
Masse moléculaire 145.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Rovelizumab]
-
Synonyms
Hu23F2G
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Commun Signal
β2 integrin regulates neutrophil trans endothelial migration following traumatic brain injury. [Abstract]2025 Feb 8;23(1):70. PMID: 39923080
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)